Replies to post #445511 on Anavex Life Sciences Corp (AVXL)

[McMagyar]

Great points the placebo dropouts I’d greatly outnumbering dosed patients..
Would have skewed these numbers ..
And wouldn’t those patient not seeing any change be the first to drop out?
They would be placebo as dosed patients saw almost immediate benefit..

The zero responders would have brought down the placebo response and create clinical significance.


What a crock of doodoo all around

[Investor2014]

Well the main issue was the strong placebo response, so I find it hard to make sense of your question.

Were there more placebo girls that dropped out, as they showed little or no significant improvement and drop out after 4 weeks with their numbers being excluded from Week 4 as well as Week 12?

Per Kaufman the issue is believed to be a disproportionate (poor) baseline scores in the placebo versus dose arm patients. This could happen simply be chance especially in a small trial. In any event dropouts must be accounted for including their baseline scores and any missing trial duration data, which the statistical methods used should ensure.